Timothy C Barabe insider trades: Cartesian Therapeutics (RNAC) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Timothy reports to the SEC
and 2 more companies
Open-market buys and sales
91 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Dec 4, 2025 | RNAC | ↑ Buy | 30,000 | $6.86 | $206K | Direct | Dec 8, 2025 (4d) |
| Aug 12, 2024 | RNAC | ↑ Buy | 7,500 | $12.70 | $95K | Direct | Aug 14, 2024 (2d) |
| May 9, 2022 | SELB | ↑ Buy | 50,000 | $0.77 | $39K | Direct | May 11, 2022 (2d) |
| Aug 18, 2021 | SELB | ↑ Buy | 9,000 | $4.00 | $36K | Direct | Aug 20, 2021 (2d) |
| Mar 26, 2021 | SELB | ↑ Buy | 10,000 | $4.10 | $41K | Direct | Mar 30, 2021 (4d) |
| Oct 13, 2020 | VEEV | ↓ Sell | 1,292 | $308.69 | $399K | Direct | Oct 15, 2020 (2d) |
| Oct 8, 2020 | VEEV | ↓ Sell | 952 | $288.00 | $274K | Direct | Oct 9, 2020 (1d) |
| Oct 6, 2020 | SELB | ↑ Buy | 50,000 | $1.68 | $84K | Direct | Oct 8, 2020 (2d) |
| Jun 23, 2020 | VEEV | ↓ Sell | 1,775 | $239.15 | $424K | Direct | Jun 24, 2020 (1d) |
| Apr 8, 2020 | VEEV | ↓ Sell | 347 | $156.00 | $54K | Direct | Apr 9, 2020 (1d) |
| Mar 17, 2020 | SELB | ↑ Buy | 5,000 | $2.00 | $10K | Direct | Mar 19, 2020 (2d) |
| Aug 13, 2019 | SELB | ↑ Buy | 10,000 | $1.72 | $17K | Direct | Aug 15, 2019 (2d) |
| Jun 18, 2019 | VEEV | ↓ Sell | 727 | $167.19 | $122K | Direct | Jun 19, 2019 (1d) |
| Apr 2, 2019 | VEEV | ↓ Sell | 727 | $127.41 | $93K | Direct | Apr 3, 2019 (1d) |
| Sep 27, 2018 | VEEV | ↓ Sell | 727 | $105.00 | $76K | Direct | Sep 28, 2018 (1d) |
| May 31, 2018 | VEEV | ↓ Sell | 701 | $77.54 | $54K | Direct | Jun 4, 2018 (4d) |
| Mar 8, 2018 | VEEV | ↓ Sell | 1,993 | $78.16 | $156K | Direct | Mar 9, 2018 (1d) |
| Nov 10, 2017 | SELB | ↑ Buy | 5,000 | $9.37 | $47K | Direct | Nov 13, 2017 (3d) |
| Mar 30, 2017 | VEEV | ↓ Sell | 1,292 | $51.04 | $66K | Direct | Apr 3, 2017 (4d) |
| Dec 30, 2016 | VEEV | ↓ Sell | 1,292 | $40.54 | $52K | Direct | Jan 4, 2017 (5d) |
| Nov 18, 2016 | OPXA | ↓ Sell | 14,914 | $0.55 | $8K | Direct | Nov 22, 2016 (4d) |
| Sep 17, 2014 | OPXA | ↑ Buy | 10,000 | $1.15 | $12K | Direct | Sep 18, 2014 (1d) |
| Aug 21, 2012 | AFFX | ↑ Buy | 10,000 | $3.75 | $38K | Direct | Aug 21, 2012 (0d) |
| Aug 17, 2012 | AFFX | ↑ Buy | 5,550 | $3.99 | $22K | Direct | Aug 17, 2012 (0d) |
| Aug 13, 2012 | AFFX | ↑ Buy | 4,450 | $3.99 | $18K | Direct | Aug 14, 2012 (1d) |
| Aug 9, 2011 | AFFX | ↑ Buy | 10,000 | $4.25 | $43K | Direct | Aug 9, 2011 (0d) |
| Aug 4, 2011 | AFFX | ↑ Buy | 10,000 | $4.75 | $48K | Direct | Aug 4, 2011 (0d) |
| Nov 19, 2010 | AFFX | ↑ Buy | 5,000 | $4.29 | $21K | Direct | Nov 19, 2010 (0d) |
| Aug 20, 2010 | AFFX | ↑ Buy | 10,000 | $4.09 | $41K | Direct | Aug 24, 2010 (4d) |
| Jul 27, 2010 | AFFX | ↑ Buy | 10,000 | $4.50 | $45K | Direct | Jul 27, 2010 (0d) |
| May 7, 2010 | AFFX | ↑ Buy | 5,000 | $6.16 | $31K | Direct | May 10, 2010 (3d) |
| Apr 27, 2010 | AFFX | ↑ Buy | 5,000 | $6.45 | $32K | Direct | Apr 27, 2010 (0d) |
| Feb 22, 2010 | HGSI | ↓ Sell | 57,200 | $30.01 | $1.7M | Direct | Feb 22, 2010 (0d) |
| Feb 3, 2010 | HGSI | ↓ Sell | 22,907 | $27.92 | $639K | Direct | Feb 4, 2010 (1d) |
| Sep 14, 2009 | HGSI | ↓ Sell10b5-1 | 35,273 | $20.00 | $705K | Direct | Sep 14, 2009 (0d) |
| Aug 18, 2009 | ARQL | ↑ Buy | 784 | $5.26 | $4K | Direct | Aug 19, 2009 (1d) |
| Aug 5, 2009 | ARQL | ↑ Buy | 104 | $5.73 | $596 | Direct | Aug 6, 2009 (1d) |
| Jul 24, 2009 | ARQL | ↑ Buy | 206 | $5.82 | $1K | Direct | Jul 28, 2009 (4d) |
| Jun 30, 2009 | HGSI | ↑ Buy | 1,000 | $1.80 | $2K | Direct | Jul 2, 2009 (2d) |
| May 18, 2009 | ARQL | ↑ Buy | 1,003 | $4.11 | $4K | Direct | May 20, 2009 (2d) |
| May 14, 2009 | ARQL | ↑ Buy | 310 | $3.87 | $1K | Direct | May 15, 2009 (1d) |
| Apr 29, 2009 | ARQL | ↑ Buy | 133 | $4.50 | $599 | Direct | Apr 30, 2009 (1d) |
| Mar 12, 2009 | ARQL | ↑ Buy | 338 | $3.55 | $1K | Direct | Mar 16, 2009 (4d) |
| Mar 4, 2009 | ARQL | ↑ Buy | 206 | $2.90 | $597 | Direct | Mar 6, 2009 (2d) |
| Feb 18, 2009 | ARQL | ↑ Buy | 1,044 | $3.95 | $4K | Direct | Feb 19, 2009 (1d) |
| Jan 20, 2009 | ARQL | ↑ Buy | 338 | $3.54 | $1K | Direct | Jan 22, 2009 (2d) |
| Nov 17, 2008 | ARQL | ↑ Buy | 2,041 | $2.90 | $6K | Direct | Nov 18, 2008 (1d) |
| Nov 14, 2008 | HGSI | ↑ Buy | 10,000 | $1.99 | $20K | Direct | Nov 17, 2008 (3d) |
| Nov 13, 2008 | HGSI | ↑ Buy | 10,000 | $2.00 | $20K | Direct | Nov 13, 2008 (0d) |
| Oct 29, 2008 | ARQL | ↑ Buy | 242 | $2.47 | $598 | Direct | Oct 31, 2008 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other RNAC insiders
Open-market trades in the last 12 months
About Timothy C Barabe's insider trades
Timothy C Barabe is a director at Cartesian Therapeutics (RNAC). Since Mar 22, 2006, Timothy has reported 76 open-market purchases worth $1.2M and 15 sales worth $4.8M on SEC Form 4. In the last 12 months: 1 buy ($206K).
1 sale (15% of the value sold) was made under a Rule 10b5-1 trading plan, which is set up months in advance and runs on a schedule, so it says little about how the insider sees the stock today.
Their filings also include grants and awards (150 filings), option exercises (36 filings), shares withheld for taxes (8 filings), shares returned to the company (2 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every RNAC insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.